CD8A and neoplasm: Animals were vaccinated with 4T1-H17 cells previously treated with doxorubicin, a known ICD inducer (88), and fewer mice were found to develop primary tumors and macrometastasis, while inducing a multifunctional response of CD4+ and CD8+ T cells, suggesting that this treatment improved the control of highly metastatic and resistant 4T1-H17 tumor cells (89).